



## **ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016**

February 23, 2016

*ACADIA to Host Conference Call and Webcast on Monday, February 29, 2016, at 8:00 a.m. Eastern Time*

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2015 on Monday, February 29, 2016, before the U.S. financial markets open. ACADIA's management will host a conference call and webcast on Monday, February 29, 2016, at 8:00 a.m. Eastern Time to discuss ACADIA's financial results and operations.

The conference call may be accessed by dialing 844-821-1109 for participants in the United States or Canada and 830-865-2550 for international callers (reference passcode 53442032). A telephone replay of the conference call may be accessed through March 14, 2016 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 53442032). The conference call also will be webcast live on ACADIA's website, [www.acadia-pharm.com](http://www.acadia-pharm.com) under the investors section and will be archived there until March 14, 2016.

### *About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson's disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA maintains a website at [www.acadia-pharm.com](http://www.acadia-pharm.com) to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.

### *Forward-Looking Statements*

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, either alone or with a partner, including clinical trials, the benefits to be derived from ACADIA's product candidates, in each case including NUPLAZID (pimavanserin), and the potential for NUPLAZID to be the first drug approved in the United States for Parkinson's disease psychosis. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and in collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2014 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160223006968/en/>

Source: ACADIA Pharmaceuticals Inc.

*ACADIA Pharmaceuticals Inc.*

*Lisa Barthelemy, Senior Director, Investor Relations  
(858) 558-2871*